DE60030732D1 - Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis - Google Patents

Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis

Info

Publication number
DE60030732D1
DE60030732D1 DE60030732T DE60030732T DE60030732D1 DE 60030732 D1 DE60030732 D1 DE 60030732D1 DE 60030732 T DE60030732 T DE 60030732T DE 60030732 T DE60030732 T DE 60030732T DE 60030732 D1 DE60030732 D1 DE 60030732D1
Authority
DE
Germany
Prior art keywords
treatment
viral myocarditis
viral
prophylaxis
octylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030732T
Other languages
English (en)
Other versions
DE60030732T2 (de
Inventor
Akira Matsumori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of DE60030732D1 publication Critical patent/DE60030732D1/de
Publication of DE60030732T2 publication Critical patent/DE60030732T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60030732T 1999-06-30 2000-06-28 Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis Expired - Lifetime DE60030732T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18529799 1999-06-30
JP18529799 1999-06-30
PCT/JP2000/004286 WO2001001978A1 (fr) 1999-06-30 2000-06-28 Compositions de medicaments servant a prevenir ou a traiter la myocardite virale

Publications (2)

Publication Number Publication Date
DE60030732D1 true DE60030732D1 (de) 2006-10-26
DE60030732T2 DE60030732T2 (de) 2007-10-11

Family

ID=16168405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030732T Expired - Lifetime DE60030732T2 (de) 1999-06-30 2000-06-28 Verwendung von 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis

Country Status (11)

Country Link
US (1) US7902261B2 (de)
EP (1) EP1201236B1 (de)
JP (1) JP4627356B2 (de)
KR (1) KR100655251B1 (de)
CN (1) CN1162149C (de)
AT (1) ATE339198T1 (de)
AU (1) AU770495B2 (de)
CA (1) CA2373833C (de)
DE (1) DE60030732T2 (de)
ES (1) ES2272293T3 (de)
WO (1) WO2001001978A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
HUE028247T2 (en) * 2003-04-08 2016-12-28 Novartis Ag A solid oral composition comprising S1P receptor agonist and sugar alcohol
PL1643983T3 (pl) * 2003-06-24 2010-10-29 Univ Connecticut Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
KR20090057399A (ko) * 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
WO2009048993A2 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
BRPI0921533A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
JPWO2013176223A1 (ja) * 2012-05-23 2016-01-14 国立大学法人大阪大学 炎症性疾患治療用医薬組成物
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN107982530B (zh) * 2017-10-23 2019-02-22 苏州大学 Semaphorin7A抗体在制备用于治疗心肌炎疾病的药物中的应用及其药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5165093A (en) * 1992-10-08 1994-05-09 E.I. Du Pont De Nemours And Company Fungicidal and miticidal aminopyrimidines
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
EP0990440B1 (de) * 1997-02-27 2008-10-29 Novartis AG Arzneimittel zubereitung enthaltend 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, ein lecithin und ein saccharid
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法

Also Published As

Publication number Publication date
CA2373833A1 (en) 2001-01-11
KR100655251B1 (ko) 2006-12-08
AU770495B2 (en) 2004-02-26
DE60030732T2 (de) 2007-10-11
CN1359290A (zh) 2002-07-17
JP2001072585A (ja) 2001-03-21
CN1162149C (zh) 2004-08-18
EP1201236B1 (de) 2006-09-13
EP1201236A4 (de) 2005-01-05
US20050234133A1 (en) 2005-10-20
WO2001001978A1 (fr) 2001-01-11
AU5570300A (en) 2001-01-22
US7902261B2 (en) 2011-03-08
CA2373833C (en) 2010-03-02
KR20020016860A (ko) 2002-03-06
EP1201236A1 (de) 2002-05-02
JP4627356B2 (ja) 2011-02-09
ATE339198T1 (de) 2006-10-15
ES2272293T3 (es) 2007-05-01
EP1201236A8 (de) 2002-10-09

Similar Documents

Publication Publication Date Title
ATE339198T1 (de) Verwendung von 2-amino-2-(2-(4- octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis
ATE445405T1 (de) Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
EA200601281A1 (ru) Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
DK1664016T3 (da) Terapeutiske midler, der er anvendelige til behandling af smerter
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
DE69327328D1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
DE60135904D1 (de) Arzneien zur behandlung von nervenerkrankungen
BRPI0409151A (pt) uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos
MY141506A (en) Virus therapeutic drug
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
DK0911026T3 (da) Creatinderivater for astma
ATE401901T1 (de) Antikrebs- und antivirale zusammensetzung
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE295159T1 (de) Bupropion zur behandlung von viralen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition